More NewsRead More
Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results for PRX-106 Oral Anti-TNF
August 03, 2015
from PR Newswire
Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis Conference
June 12, 2015
Protalix BioTherapeutics Reports Full Year 2014 Financial Results and Provides Corporate Update
March 12, 2015
Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its PRX 106 Oral Anti TNF
October 05, 2015
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here